CombinatoRx   
CombinatoRx (NasdaqGS:CRXX) has a proprietary platform to screen drug combinations in vitro and has thus far introduced six products into the clinic based on this platform. The company focuses on unique combinations of drugs that have already been approved by the FDA. With the well-publicized, safety-related failures of approved drugs after marketing had begun, we believe the company’s focus on combinations of existing drugs gives it a highly attractive drug development model. The company has created a current pipeline of drug candidates consisting of proprietary products with reduced safety risks in cancer, inflammation and other disease states, which have large addressable markets. The company went public in December 2005 to raise proceeds for development purposes and has raised additional funds in private placements. We believe that the company’s products are unusually attractive and the company has the potential to provide a high return on our investment.